Financial Position and Capital Needs - The company has an accumulated deficit of $342.2 million from inception through December 31, 2025, and expects to continue incurring losses in the future [72]. - The company has never generated revenue from product sales and does not anticipate doing so for at least four years [71]. - The company will need to raise additional capital in the near future to fund operations and research and development programs for the next 12 months [72]. - The company has limited capital and substantial accumulated deficit, raising concerns about its ability to fund operations and research [70]. - The company expects that its current cash position will not be sufficient to fund operations over the next 12 months, indicating a potential need for significant additional capital [193]. Clinical Development Risks - A Phase 2a study for the CC-42344 Influenza A product candidate must be redone due to an insufficient infection rate, resulting in a $6.3 million investment that may be partially lost [83]. - The company is subject to various risks and uncertainties in pharmaceutical product development, making it difficult to predict expenses and profitability [76]. - The company’s ability to generate revenue and achieve profitability depends on successfully completing clinical trials and obtaining regulatory approvals [73]. - The company may face significant delays or failures in clinical trials, impacting its ability to generate product revenues [109]. - Approximately 70% of drugs proceed past Phase 1 studies, 33% past Phase 2, and only 25%-30% past Phase 3 in the FDA approval process, highlighting the challenges in drug development [107]. - Adverse events observed during clinical trials could lead to interruptions or halts in trials, negatively impacting regulatory approval chances [116]. Competition and Market Dynamics - The company faces significant competition from major companies that have developed vaccines or treatments, which could adversely affect its market share [84]. - The biotechnology and pharmaceutical industries are intensely competitive, with competitors having greater financial and technical resources, which could adversely affect the company's operating results [146]. - The company’s product candidates are in preclinical or early clinical development stages, facing competition from existing approved products and other candidates in development [147]. - Market acceptance of product candidates will depend on factors such as clinical safety, efficacy, pricing, and reimbursement policies from third-party payors [158][159]. - The company may struggle to achieve profitability if adequate coverage and reimbursement are not available for its product candidates, especially with ongoing changes in healthcare policies [161]. Regulatory and Compliance Challenges - The company must comply with current Good Clinical Practices (cGCPs) to ensure the credibility of clinical data, with non-compliance potentially leading to additional trials [99]. - Regulatory authorities may impose restrictions on approved products, including additional post-marketing testing requirements or withdrawal of approval [121]. - The company has limited experience in managing preclinical development and clinical trials, which may hinder the ability to obtain marketing approvals [129]. - The company is subject to various federal and state healthcare fraud and abuse laws, and non-compliance could result in significant penalties [172]. Intellectual Property and Legal Risks - The company relies on a combination of patents and trade secrets to protect intellectual property, but there is no guarantee that these protections will be effective [131]. - Third-party intellectual property infringement claims could delay development and commercialization efforts, impacting future prospects [135]. - The company may face significant litigation expenses and management distraction from defending against intellectual property claims [138]. - The company may need to obtain additional licenses from third parties to advance research or commercialize product candidates, which could significantly harm its business if not acquired on reasonable terms [143]. - The company may face expensive and time-consuming lawsuits to protect its patents, which could result in adverse outcomes affecting patent validity [140]. Operational and Management Challenges - The company has experienced delays and increased costs in research due to staffing shortages at CROs caused by the COVID-19 pandemic [89]. - The company currently has 10 full-time employees and plans to expand its workforce, which may pose management challenges and operational disruptions [171]. - Future partners may not allocate sufficient resources for the commercialization of product candidates, impacting revenue generation [165]. - The company lacks a sales and marketing team experienced in pharmaceutical product distribution, which may hinder revenue generation from product sales [164]. Market and Economic Conditions - The volume of drug pricing-related legislation is increasing, which could disrupt access to medicines and reduce the potential market for the company's products [162]. - The company faces uncertainties surrounding tariffs and geopolitical conflicts, which could lead to prolonged inflation and reduced economic activity [191]. - The company is subject to significant market volatility, with potential adverse effects on its business due to economic downturns or recessions [192]. - Cybersecurity threats pose risks to the company's proprietary technology and information, which could lead to significant operational disruptions and reputational damage [150][154]. Stock and Shareholder Considerations - The stock price and trading volume of the company have historically been volatile, with potential for temporary increases [183]. - The company has 7,222,821 warrants outstanding as of the date of the report, which could result in volatility and dilution to existing shareholders if exercised [197]. - Future sales of substantial amounts of shares in the public market could cause the market price of the company's common stock to decline significantly, even if business performance is strong [198]. - The absence of research coverage from major brokerage firms could limit the development of an active market for the company's common stock, impacting its ability to attract new investors [200]. - The company may issue preferred stock that could complicate third-party acquisitions and potentially depress its stock price [201].

Financial Performance - Cocrystal Pharma reported a net loss of $8.8 million, or $0.78 per share, for 2025, a significant decrease from a net loss of $17.5 million, or $1.72 per share, in 2024[18]. - Net loss improved from $(17,504,000) in 2024 to $(8,831,000) in 2025, reflecting a reduction of about 49.6%[25]. - Net loss per common share improved from $(1.72) in 2024 to $(0.78) in 2025, a decrease of approximately 54.4%[25]. Expenses - Research and development expenses for 2025 were $5.1 million, down from $12.5 million in 2024, primarily due to the winddown of the Phase 2a influenza study[17]. - Total operating expenses decreased from $17,878,000 in 2024 to $9,019,000 in 2025, a decrease of approximately 49.6%[25]. - Research and development expenses decreased significantly from $12,537,000 in 2024 to $5,055,000 in 2025, a reduction of about 59.7%[25]. - General and administrative expenses decreased to $4.0 million in 2025 from $5.3 million in 2024, attributed to reductions in compensation and corporate expenses[17]. - General and administrative expenses decreased from $5,341,000 in 2024 to $3,964,000 in 2025, a decline of approximately 25.7%[25]. Assets and Liabilities - Cocrystal reported unrestricted cash of $7.7 million as of December 31, 2025, compared to $9.9 million at the end of 2024[18]. - Total current assets decreased from $11,580,000 in 2024 to $8,134,000 in 2025, a decline of approximately 30.5%[23]. - Total assets decreased from $13,456,000 in 2024 to $9,712,000 in 2025, representing a reduction of about 28.5%[23]. - Total liabilities decreased from $3,933,000 in 2024 to $3,381,000 in 2025, a reduction of about 14.0%[23]. - Stockholders' equity decreased from $9,523,000 in 2024 to $6,331,000 in 2025, a decline of approximately 33.0%[23]. Share Information - The company had working capital of $5.9 million and 11.3 million common shares outstanding as of December 31, 2025[18]. - Weighted average number of common shares outstanding increased from 10,174 in 2024 to 11,290 in 2025, an increase of about 10.9%[25]. Product Development - The company is developing CDI-988, the first oral antiviral candidate for norovirus treatment, with a Phase 1b study currently underway at Emory University[4]. - CDI-988 has shown in vitro activity against multiple norovirus strains and is also being explored for its potential against coronaviruses[8]. - Cocrystal plans to continue the development of oral CC-42344 as a treatment for pandemic and seasonal influenza A, following favorable Phase 1 results[15]. Market Opportunity - Norovirus causes approximately 685 million global cases annually, with a $60 billion economic impact, highlighting a significant unmet medical need[7]. - The global COVID-19 therapeutics market is projected to exceed $16 billion annually by the end of 2031, indicating a substantial market opportunity for Cocrystal's antiviral products[13].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Cocrystal Pharma is advancing its antiviral product pipeline, particularly focusing on CDI-988, an oral antiviral candidate for norovirus treatment and prevention, amidst a significant unmet medical need in the market [1][7][18]. Antiviral Product Pipeline Overview - The company utilizes a structure-based drug discovery platform to develop broad-spectrum antivirals that target conserved regions of viral proteins, enhancing efficacy against mutations and reducing side effects [4]. - CDI-988 is designed as a direct-acting oral antiviral targeting the 3CL protease of noroviruses and has potential applications against coronaviruses [3][15]. Norovirus Program - Norovirus causes approximately 685 million cases globally each year, with a $60 billion economic impact, highlighting the urgent need for effective treatments [6]. - CDI-988 is currently undergoing a Phase 1b challenge study at Emory University, with the primary endpoint focused on reducing clinical symptoms [2][7]. Financial Results - For the year ended December 31, 2025, Cocrystal reported a net loss of $8.8 million, a significant reduction from the $17.5 million loss in 2024, indicating improved financial management [17]. - Research and development expenses decreased to $5.1 million in 2025 from $12.5 million in 2024, primarily due to the winding down of previous studies [16]. Influenza Programs - The company is also developing CC-42344, a novel PB2 inhibitor for influenza, which has shown in vitro activity against resistant strains [11][13]. - Influenza poses a major health threat with approximately 1 billion cases annually, leading to significant healthcare costs [10]. Market Potential - The global market for COVID-19 therapeutics is projected to exceed $16 billion annually by the end of 2031, indicating substantial growth opportunities for antiviral treatments [14].

Core Viewpoint - Cocrystal Pharma has initiated a Phase 1b clinical trial for CDI-988, an oral antiviral aimed at preventing and treating norovirus infections, addressing a significant global health need [1][2][3] Group 1: Clinical Study Details - The Phase 1b study is randomized, double-blind, and placebo-controlled, enrolling up to 40 healthy subjects aged 18-49, all of whom will be infected with the GII.2 norovirus strain [2][7] - The primary endpoint of the study is to evaluate the efficacy of CDI-988 compared to placebo in reducing clinical symptoms, with secondary endpoints including viral shedding, disease severity, safety, and pharmacokinetics [7] Group 2: Drug Development and Technology - CDI-988 is the first direct-acting oral antiviral developed specifically for norovirus, targeting a conserved region of the viral 3CL protease found in all known norovirus strains [1][6] - Cocrystal's proprietary structure-based drug discovery platform enables the development of novel antiviral agents by providing detailed structural insights for drug design [5][9] Group 3: Norovirus Impact - Norovirus causes an estimated 685 million cases globally each year, with a significant economic impact of $60 billion, highlighting the urgent need for effective treatments [4][6] - In the U.S., norovirus is responsible for approximately 21 million infections annually, leading to substantial healthcare costs and hospitalizations [4]

Core Insights - Cocrystal Pharma, Inc. is advancing its oral protease inhibitor CDI-988 for norovirus treatment and prevention, with initial study results to be presented at ICAR2026 [1][2][3] Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral therapeutics targeting various viruses, including noroviruses and coronaviruses [6] Product Development - CDI-988 is the first oral antiviral drug candidate aimed at preventing and treating acute norovirus gastroenteritis, developed using a proprietary structure-based drug discovery platform [2][3] - The ongoing Phase 1b challenge study at Emory University School of Medicine evaluates CDI-988 as both a prophylactic and therapeutic option for norovirus infection [2][3] Industry Context - Norovirus is a highly contagious virus causing acute gastroenteritis, leading to approximately 200,000 deaths globally each year and an estimated societal cost of $60 billion [5] - In the U.S., norovirus accounts for about 21 million cases of acute gastroenteritis annually, resulting in significant hospitalizations and economic burden [5]

Core Insights - Cocrystal Pharma has received approval from the Institutional Review Board at Emory University to initiate a Phase 1b human challenge study for CDI-988, aimed at preventing and treating norovirus infections [1][4] - CDI-988 is the first oral antiviral drug candidate specifically designed to target norovirus, including strains GII.4 and GII.17 [2] - The Phase 1b study will involve up to 40 healthy subjects and will assess the efficacy, safety, and pharmacokinetics of CDI-988 [3] Company Developments - The study's primary endpoint is to evaluate the reduction in clinical symptoms, while secondary endpoints include viral shedding and disease severity [3] - Cocrystal's President highlighted the significance of this study in addressing the global burden of norovirus, which causes approximately 700 million cases annually [5] - CDI-988 has shown favorable safety and tolerability data in previous Phase 1 trials, with the highest dose being 1200 mg [6] Industry Context - Norovirus is a highly contagious virus responsible for around 200,000 deaths globally each year, with significant economic impacts estimated at $60 billion [7] - In the U.S., norovirus leads to about 21 million cases of acute gastroenteritis annually, resulting in substantial healthcare costs [7] - There are currently no approved treatments or vaccines for norovirus, highlighting the potential market opportunity for CDI-988 [9]

Group 1 - Cocrystal Pharma, Inc. will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025 [1] - The conference will take place at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida [1] - Interested investors can attend the conference at a discounted rate using the code COCPNOBLECON [2] Group 2 - Cocrystal Pharma is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [4] - The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs [4] Group 3 - Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984 [3] - The firm provides institutional-quality equity research, merchant and investment banking, and order execution services [3] - Noble launched Channelchek in 2018, an investor community dedicated to public small and micro-cap companies, offering free institutional-quality research [3]

Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [4] - The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs [4] Upcoming Event - James Martin, CFO and co-CEO of Cocrystal, will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, at 10:00 am Eastern time [1] - The conference will take place at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida [1] - Interested investors can attend the conference at a discounted rate using the code COCPNOBLECON [2] - A video webcast of the presentation will be available on December 4, 2025, and archived for 90 days on the company's website [2] About Noble Capital Markets - Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984 [3] - The firm provides institutional-quality equity research, merchant and investment banking, and order execution services [3] - In 2018, Noble launched Channelchek, an investor community dedicated to public small and micro-cap companies, offering free institutional-quality research without a subscription [3]

Financial Performance - Net loss for Q3 2025 was $2.0 million, or $0.19 per share, compared to a net loss of $4.9 million, or $0.49 per share in Q3 2024[13] - The net loss for the first nine months of 2025 was $6.4 million, or $0.61 per share, compared to a net loss of $14.2 million, or $1.40 per share in the first nine months of 2024[14] - Net loss for the three months ended September 30, 2025, was $2,049,000, compared to a net loss of $4,939,000 for the same period in 2024, indicating an improvement of approximately 58.5%[24] - Net loss per common share for the three months ended September 30, 2025, was $(0.19), an improvement from $(0.49) for the same period in 2024, reflecting a decrease in loss per share of approximately 61.2%[24] Expenses - Research and development (R&D) expenses for Q3 2025 were $954,000, a decrease of 70% compared to $3.2 million in Q3 2024[12] - General and administrative (G&A) expenses for Q3 2025 were $1.1 million, down 39% from $1.8 million in Q3 2024[12] - For the first nine months of 2025, R&D expenses totaled $3.4 million, a reduction of 68% from $10.5 million in the same period of 2024[14] - Research and development expenses for the nine months ended September 30, 2025, were $3,436,000, down from $10,500,000 for the same period in 2024, a decrease of about 67.3%[24] - General and administrative expenses for the three months ended September 30, 2025, were $1,135,000, compared to $1,800,000 for the same period in 2024, reflecting a decrease of approximately 37.2%[24] - Total operating expenses for the three months ended September 30, 2025, were $2,089,000, down from $5,042,000 in 2024, a reduction of about 58.6%[24] Cash and Assets - As of September 30, 2025, unrestricted cash was $7.7 million, down from $9.9 million as of December 31, 2024[15] - Total current assets decreased from $11,580,000 as of December 31, 2024, to $8,782,000 as of September 30, 2025, representing a decline of approximately 24.0%[22] Liabilities - Total liabilities decreased from $3,933,000 as of December 31, 2024, to $2,777,000 as of September 30, 2025, a reduction of about 29.4%[22] Funding and Awards - Cocrystal raised gross proceeds of $4.7 million from a registered direct offering in September 2025, and an additional $1.03 million from a private placement in October 2025[3][16] - Cocrystal received a Small Business Innovation Research (SBIR) award from the NIH for $500,000 to advance its influenza A/B replication inhibitor program[3][10] Future Outlook - The company expects to begin enrolling participants for the CDI-988 Phase 1b norovirus challenge study in Q1 2026[4] - The global COVID-19 therapeutics market is projected to exceed $16 billion annually by the end of 2031[11] Shareholder Information - The weighted average number of common shares outstanding increased from 10,174,000 as of September 30, 2024, to 10,991,000 as of September 30, 2025, an increase of approximately 8.0%[24] Interest Income - Interest income for the nine months ended September 30, 2025, was $482,000, compared to $87,000 for the same period in 2024, representing a significant increase of approximately 453.4%[24] Accumulated Deficit - The accumulated deficit increased from $(333,418,000) as of December 31, 2024, to $(339,823,000) as of September 30, 2025, indicating a deterioration of about 1.2%[22]